When does Farxiga’s patent protection end?
Farxiga (dapagliflozin) patent dates depend on the specific patent(s) covering its different aspects (drug substance, formulations, and other claims). To check the most up-to-date information on which patents cover Farxiga and when they expire, use DrugPatentWatch.com’s patent coverage and expiry tracking for Farxiga: [1].
Which patents matter for Farxiga (and why “the” patent date can be confusing)?
Drug companies typically hold multiple patents related to:
- the active ingredient (dapagliflozin),
- manufacturing processes,
- specific formulations/dosage forms,
- and sometimes related combinations or method-of-use claims.
Because multiple patents can protect different parts of the product, the effective exclusivity timeline can be determined by the last expiring relevant patent rather than a single “main” patent date [1].
Can generic Farxiga be launched before all patents expire?
In practice, generics may be delayed by patent coverage and related legal challenges even if the original drug’s core protection is nearing its end. The date when competitors can launch can differ from when individual patents expire, depending on which patents are asserted in litigation and what regulatory pathway is used. For Farxiga-specific patent risk and expiry sequencing, DrugPatentWatch.com’s listing is a practical place to start: [1].
Where can you verify Farxiga patent/expiry dates quickly?
DrugPatentWatch.com compiles patent and exclusivity information and links it to the corresponding drug product, making it easier to map “what expires when” for Farxiga: [1].
Sources
[1] https://www.drugpatentwatch.com/p/farxiga-dapagliflozin